Similar Papers

Paper Title
Journal
Date
Author
Delayed Signs of Early Disability Progression After 8.5 Years of Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis (S46.003)
Martin Weber ... Ludwig Kappos
Neurology | VOL. 100
Martin Weber, et. al.Martin Weber ... Ludwig Kappos
25 Apr 2023
Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis; the Phase IIIb ENSEMBLE Study (S46.004)
Robert Bermel ... Jens Wuerfel
Neurology | VOL. 100
Robert Bermel, et. al.Robert Bermel ... Jens Wuerfel
25 Apr 2023
An Interim Analysis of Efficacy and Safety Data in Black and Hispanic Patients With Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial (S31.006)
Evanthia Bernitsas ... Richard Sater
Neurology | VOL. 100
Evanthia Bernitsas, et. al.Evanthia Bernitsas ... Richard Sater
25 Apr 2023
Correlations Between Early MRI Parameters and Long-term Clinical Outcomes in Phase 3 and Open-label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis (P5-3.010)
Douglas L Arnold ... Bruce A C Cree
Neurology | VOL. 100
Douglas L Arnold, et. al.Douglas L Arnold ... Bruce A C Cree
25 Apr 2023
View more papers

More From: Neurology

Paper Title
Journal
Date
Author
Teaching NeuroImage: Vessel Wall Imaging of a Vertebral Artery Web.
Jiashu Li ... Xingquan Zhao
Neurology | VOL. 104
Jiashu Li, et. al.Jiashu Li ... Xingquan Zhao
14 Jan 2025
Teaching NeuroImage: Wallerian Degeneration of the Corticospinal Tract After Cerebral Hemorrhage.
Kunyi Li ... Lan Wen
Neurology | VOL. 104
Kunyi Li, et. al.Kunyi Li ... Lan Wen
14 Jan 2025
Antibiotic Use and Subsequent Cognitive Decline and Dementia Risk in Healthy Older Adults.
Yiqing Wang ... Andrew T Chan
Neurology | VOL. 104
Yiqing Wang, et. al.Yiqing Wang ... Andrew T Chan
14 Jan 2025
More Questions Than Answers About Poststroke Cognitive Impairment and Dementia.
Deborah A Levine
Neurology | VOL. 104
Deborah A LevineDeborah A Levine
14 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.